<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>c-Myc has been implicated in a variety of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> including Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Targeting c-Myc driven growth pathways could be therapeutically useful but might require the identification of critical downstream proteins </plain></SENT>
<SENT sid="2" pm="."><plain>Here we show that the serine-threonine kinase PBK/TOPK is frequently overexpressed in high-grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and its expression is positively correlated to that of c-Myc and E2F1 </plain></SENT>
<SENT sid="3" pm="."><plain>Further we demonstrate that c-Myc regulates PBK expression through E2F1 </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, inhibition of c-Myc, E2F1 or PBK comparably decreased cell growth and survival </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, a c-Myc-E2F1-PBK signaling pathway operates in high-grade <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and may provide a useful target for novel <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> therapeutics </plain></SENT>
</text></document>